-
Imagine Dragons frontman chases childhood video game dream
-
Teenage sprint star Gout powers to 200m win in blistering 19.67sec
-
China's energy strategy pays off as Mideast war cramps supplies: analysts
-
Hungarians vote in closely watched election, with Orban's rule on line
-
Mideast war takes a bite out of Filipino street food vendors
-
Crime-weary Peru votes for ninth president in a decade
-
Vance says talks failed to reach deal with Iran on ending Mideast war
-
New York's teen spirit frustrates Messi, Miami
-
Vance says talks failed to reach agreement with Iran
-
McIlroy falters, shares Masters lead with surging Young
-
'Stop hiring humans'? Silicon Valley confronts AI job panic
-
Force rue missed opportunities after another Super Rugby defeat
-
Ireland's Lowry becomes first with two Masters aces
-
'Mental toughness' hailed after Reds snap 15-year Crusaders curse
-
Justin Bieber fans flood Coachella festival for headlining show
-
Saturday charge has Young in sight of first major title at Masters
-
McIlroy looking for answers after squandered Masters lead
-
McIlroy and Young share lead after Masters third round
-
Lavelle marks 100th cap with goal in US win over Japan
-
Artemis crew urges unity on 'lifeboat' Earth
-
US, Iran talks extend into second day as strait showdown deepens
-
Former heavyweight king Fury outpoints Makhmudov, calls out Joshua
-
Former heavyweight king Fury outpoints Makhmudov on ring return
-
US says warships transit Strait of Hormuz in mine clearance op
-
Two-time champ Scheffler surges up Masters leaderboard
-
McIlroy scrambles to hold off rivals and keep Masters lead
-
Milan's Serie A title hopes in tatters after shock Udinese defeat, Juve fourth
-
Easter truce between Russia and Ukraine falters
-
US warships transit Strait of Hormuz in mine clearance op
-
Playoff seedings on line as grueling NBA regular-season comes to close
-
Ngumoha's 'special' impact no surprise to Slot
-
Arsenal suffer major title blow as Liverpool earn vital win
-
US, Iran hold high-level peace talks in Pakistan
-
Over 200 arrested at pro-Palestinian rally in London
-
McIlroy tees off with six-stroke Masters lead
-
Record-breaking Bayern march closer to Bundesliga title
-
World champions England make winning start to Women's Six Nations
-
Yamal shines as Barca thrash Espanyol to extend Liga lead
-
Drean double sets Toulon up for Champions Cup semi against Leinster
-
Salah, Ngumoha ease Liverpool crisis with Fulham win
-
Arsenal suffer huge title blow as Liverpool earn vital win
-
Samson smashes hundred as Chennai notch first win of IPL season
-
Bayern Munich set Bundesliga record with 102nd goal of season
-
Milan's Serie A title hopes in tatters after shock Udinese defeat
-
Alcaraz and Sinner battle for No.1 spot in Monte Carlo final
-
In fiery speech, Pope Leo says 'Enough to war!'
-
Andreeva to face Potapova in Linz WTA final
-
Holders Italy, Britain into BJK Cup finals, USA knocked out
-
Arsenal suffer title 'punch' by Bournemouth, Everton hold Brentford
-
Drean double breaks Glasgow hearts as Toulon reach Champions Cup semis
Canada health authority approves Pfizer's anti-Covid pill
Canada's health authority said Monday it has approved Pfizer's anti-Covid pill, Paxlovid, for adults at high risk of progressing to serious disease.
The oral treatment was approved after an "expedited review," Health Canada said in a statement on its website, adding that it would continue to monitor its safety and effectiveness.
"No drug, including PAXLOVID TM, is a substitute for vaccination," the statement added.
The drug, which comprises two types of tablet, is the first Covid-19 therapy which can be taken at home, and is potentially a huge step towards ending the pandemic.
"Today's announcement is particularly important as access to easy-to-use treatments could help to reduce the severity of Covid-19 in adults who become newly infected and are at high-risk of progressing to serious illness," said Theresa Tam, Canada's chief public health officer.
The approval comes as Canada, like many countries, has been struggling to contain the Omicron variant of Covid-19.
The French-speaking province of Quebec recently announced it would levy a tax on the unvaccinated, arguing they impose a burden on everyone else.
Paxlovid has so far been authorized in a handful of countries including the United States and Israel, while the European Union has allowed member states to use it ahead of formal approval as an emergency measure against Omicron.
Unlike vaccines, it does not target the ever-evolving spike protein which the coronavirus uses to invade cells.
It should therefore in theory be more variant-proof, and the company has said preliminary lab studies have backed up that hypothesis.
H.Darwish--SF-PST